Genmab
Genmab A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to developing differentiated antibody therapeutics. Founded in 1999, Genmab has made significant strides in the biopharmaceutical industry, focusing primarily on oncology and immunology. With a robust pipeline of proprietary and partnered products, Genmab's core offerings include monoclonal antibodies that target various cancers, distinguished by their unique mechanisms of action. The company has achieved notable milestones, including the successful development of its flagship product, Darzalex, which has transformed treatment paradigms for multiple myeloma. Positioned as a key player in the global biotechnology landscape, Genmab continues to expand its influence through strategic collaborations and a commitment to scientific excellence, solidifying its reputation as a pioneer in the field.
DitchCarbon Score
How does Genmab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genmab's score of 42 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genmab's reported carbon emissions
In 2023, Genmab reported total carbon emissions of approximately 151,463,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 317,000 kg CO2e, while Scope 2 emissions totalled approximately 238,000 kg CO2e. The majority of their emissions, approximately 150,908,000 kg CO2e, fell under Scope 3, which includes indirect emissions from their value chain. In 2024, Genmab's total emissions increased to about 189,673,000 kg CO2e, with Scope 1 emissions rising to approximately 534,000 kg CO2e and Scope 2 emissions reported at about 1,163,000 kg CO2e. Scope 3 emissions also saw an increase, reaching approximately 187,976,000 kg CO2e. Despite these figures, Genmab has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The company has reported carbon emissions per employee, which increased from about 4,160 kg CO2e in 2021 to approximately 6,740 kg CO2e in 2023, indicating a growing intensity of emissions relative to their workforce. Genmab's headquarters is located in Denmark (DK), and while they have not committed to specific reduction targets or climate pledges, their emissions data reflects a comprehensive approach to tracking and reporting their carbon footprint across all relevant scopes.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 341,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 298,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genmab is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
